SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study.

ABSTRACT:

Background

Vaccines offer people with multiple sclerosis (PwMS) an effective protection against severe COVID-19 disease courses. However, representative real-world data on the tolerability of SARS-CoV-2 vaccines in PwMS are limited. We aimed at analysing vaccination reactions (VRs) and MS deterioration following SARS-CoV-2 vaccinations in German and United Kingdom (UK) PwMS, especially regarding gender-specific differences.

Methods

The German Multiple Sclerosis Society and the UK MS Registry acquired health data via an online system following the first (X¹) and second SARS-CoV-2 vaccination (X²), respectively: sociodemographic and clinical data, vaccines used, VRs, MS deterioration (worsened or new MS symptoms, Germany only) and relapses (Germany only).

SUBMITTER: Frahm N 

PROVIDER: S-EPMC9438509 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature